<DOC>
	<DOCNO>NCT00004406</DOCNO>
	<brief_summary>OBJECTIVES : I . Determine effect human parathyroid hormone ( 1-34 ) bone mass middle-aged men idiopathic osteoporosis .</brief_summary>
	<brief_title>Randomized Study Human Parathyroid Hormone Middle-Aged Men With Idiopathic Osteoporosis</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , double blind , placebo control study . All patient self-administer daily subcutaneous injection human parathyroid hormone ( 1-34 ) placebo period 2.5 year . Patients follow regularly unacceptable toxicity . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Osteoporosis define : Bone mineral density lumbar spine femoral neck 2.5 standard deviation peak bone mass reference value ( T score less 2.5 ) No family history male osteoporosis No metabolic bone disease Prior/Concurrent Therapy Endocrine therapy : No concurrent glucocorticoid therapy No prior steroid use Surgery : No prior gastrointestinal tract surgery Other : No prior concurrent anticonvulsant therapy Patient Characteristics Hematopoietic : Normal CBC Hepatic : Normal liver function Renal : Normal renal function Other : Normal thyroid function Normal adrenal function Normal gonadal status No myeloma malignancy No alcoholism , hypercortisolism diabetes mellitus No gastrointestinal tract disease disorder associate malabsorption</criteria>
	<gender>Male</gender>
	<minimum_age>29 Years</minimum_age>
	<maximum_age>67 Years</maximum_age>
	<verification_date>January 2000</verification_date>
	<keyword>disease-related problem/condition</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>rare disease</keyword>
</DOC>